L26/P-718 Frozen Embryo Transfer outcomes in non-ovulatory patients: Letrozole/low-dose FSH-based protocol versus the standard Estradiol/Progesterone protocol
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1045 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von E. Cetin und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do reproductive outcomes differ between a letrozole/low-dose FSH-based (Letrozole/FSH) FET protocol and a standard estradiol/progesterone (E2/P4) protocol in non-ovulatory patients? Summary answer In non-ovulatory patients Letrozole/FSH FET protocol can achieve similar reproductive outcomes as the standard E2/P4 protocols. What is known already Frozen embryo transfer (FET) in non-ovulatory patients is traditionally performed using hormonally controlled (HC) cycles with exogenous micronized E2/P4. While effective, HC E2/P4 cycles lack ovulation and corpus luteum formation, rely on supraphysiologic hormone exposure, and require prolonged medication use. Other ovulation-based FET protocols using Letrozole or low dose FSH offers a more physiologic alternative. Such protocols have been used successfully during FET cycle in non-ovulatory patients. Ovulation-based FET using letrozole combined with low-dose FSH can also be used during FET in non-ovulatory patients. However, direct comparisons between letrozole/FSH-based FET and standard HC E2/P4 protocols in non-ovulatory patients remain scarce. Study design, size, duration Single-center retrospective study including 271 cycles of FET (84 letrozole/FSH and 187 HC E2/P4) in 261 non-ovulatory patients (January 2006 and December 2024), excluding donor and biopsied blastocysts for preimplantation genetic diagnosis. In the letrozole/ FSH group, letrozole 5 mg was given for 5 days starting cycle day 2. FSH (25-37.5 IU) was started on last day of letrozole, first every other day then daily. Outcomes included implantation, clinical pregnancy, miscarriage, and delivery rates. Participants/materials, setting, methods In Letrozole/FSH group, HCG (10,000 IU) was administered when a follicle was >16mm, and endometrial thickness >8mm; vaginal micronized progesterone and vaginal micronized estradiol were started 4 days later. Blastocyst transfer was performed 7 days after the day of HCG triggering. In HC E2/P4 protocol; vaginal E2 and patches, with/without GnRH agonist were used. Progesterone in oil 100mg IM was administered when endometrial thickness >8mm. Blastocyst transfer was performed 6 days after progesterone administration. Main results and the role of chance Overall, there were no significant differences in baseline characteristics between protocols, except for lower rates of primary infertility (27.5% vs 59.6%, p < 0.001) and less cycles with no high-grade embryos (48.8% vs 72.7%, <0.001) in the letrozole/FSH group compared to E2/P4. In Letrozole/FSH group, there were significantly higher implantation (65.5% vs 36.4%, p = 0.002), clinical pregnancy (67.9% vs 49.2%, p = 0.004), and delivery rates (57.1% vs 40.6%, p = 0.012) rates compared to E2/P4 group, respectively, despite higher miscarriage rates (15.8% vs 2.2%, p = 0.002). Generalized estimating equation logistic regression was performed to account for more than one FET per patient and adjust for potential confounders (primary/secondary infertility and number of high-quality blastocysts transferred). Results were no longer significant after adjustment [adjusted OR (95%CI): Clinical pregnancy 1.76 (0.94-3.29), p = 0.075; Miscarriage: 3.95 (0.76-20.46), p = 0.101; Delivery: 1.68 (0.92-3.06), p = 0.092] (E2/P4 group as reference). After stratification by age, results suggested no significant differences between the two groups respectively except for higher clinical pregnancy (74.5% vs. 51.6%, p = 0.007) and miscarriage rates (17.1% vs 0%, p = 0.001) with Letrozole/FSH group, in the less than 35 years of age stratum. After adjustment results remained significant for clinical pregnancy [adjustment OR (95%CI): 3.02 (1.16-7.89), p = 0.024]. Limitations, reasons for caution The retrospective design introduces potential residual confounding, and protocol selection was not randomized. However, this pilot study explored the use letrozole/low dose FSH to induce ovulation and preparing the endometrial cavity for embryo transfer to mimic the natural cycle environment. Wider implications of the findings A letrozole/FSH-based FET protocol represents a physiologic and an alternative option to HC E2/P4 protocol for non-ovulatory patients. In addition, this protocol is also suitable for patients in whom high dose Estradiol use is contraindicated. Furthermore, Letrozole/FSH protocol could be attempted after failure with HC E2/P4 protocol. Trial registration number No
Zitieren
APA
Cetin, E., Cherouveim, P., Clever, L., Daviskiba, S., Abozaid, T., Fakih, M., & Abuzeid, M. (2026). L26/P-718 Frozen Embryo Transfer outcomes in non-ovulatory patients: Letrozole/low-dose FSH-based protocol versus the standard Estradiol/Progesterone protocol. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1045
Vancouver
Cetin E, Cherouveim P, Clever L, Daviskiba S, Abozaid T, Fakih M, et al. L26/P-718 Frozen Embryo Transfer outcomes in non-ovulatory patients: Letrozole/low-dose FSH-based protocol versus the standard Estradiol/Progesterone protocol. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1045
BibTeX
@article{Cetin2026,
author = {Cetin, E. and Cherouveim, P. and Clever, L. and Daviskiba, S. and Abozaid, T. and Fakih, M. and Abuzeid, M.},
title = {L26/P-718 Frozen Embryo Transfer outcomes in non-ovulatory patients: Letrozole/low-dose FSH-based protocol versus the standard Estradiol/Progesterone protocol},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1045}
}
EUVIMED